Does Labelling Amount to Manufacture Under Central Excise Act? Supreme Court Clarifies
Commissioner of Central Excise Belapur vs Jindal Drugs Ltd.
Listen to this judgment
• 4 min readKey Takeaways
• A court cannot deny cenvat credit merely because labelling does not enhance marketability.
• Section 35L(1)(b) of the Central Excise Act allows appeals against CESTAT orders.
• Note 3 to Chapter 18 of the Central Excise Tariff Act defines labelling as a manufacturing process.
• Post-amendment, labelling and repacking are independent processes under the Central Excise Tariff Act.
• Extended limitation periods cannot be applied if there is no suppression of facts.
Introduction
In a significant ruling, the Supreme Court of India addressed the issue of whether the activity of labelling constitutes manufacture under the Central Excise Act. The case, Commissioner of Central Excise Belapur vs Jindal Drugs Ltd., involved the interpretation of Note 3 to Chapter 18 of the Central Excise Tariff Act, which has implications for the eligibility of cenvat credit and rebate claims. The Court's decision clarifies the legal standing of labelling activities in the context of excise duties and manufacturing processes.
Case Background
The case arose from an appeal by the Commissioner of Central Excise against the order of the Customs, Excise and Service Tax Appellate Tribunal (CESTAT), which had allowed the appeal of Jindal Drugs Ltd. The respondent, engaged in the business of exporting cocoa butter and cocoa powder, had claimed cenvat credit for duties paid on goods manufactured at its Jammu unit and subsequently labelled at its Taloja unit before export.
The appellant contended that the activity of labelling did not amount to manufacture, as it did not enhance the marketability of the goods. The CESTAT, however, held that labelling constituted manufacture under Note 3 to Chapter 18 of the Central Excise Tariff Act, allowing the respondent to avail of cenvat credit and rebate on duties paid.
What The Lower Authorities Held
The original order by the Commissioner of Central Excise concluded that the labelling activity at the Taloja unit did not amount to manufacture, as the goods were already marketable upon arrival from Jammu. The Commissioner issued a show cause notice demanding the recovery of cenvat credit and rebate claims, asserting that the respondent had suppressed material facts regarding its operations.
The CESTAT's decision was split, with the Judicial Member supporting the respondent's position that labelling constituted manufacture, while the Technical Member disagreed, asserting that no manufacturing activity occurred. The matter was referred to a third member, who ultimately sided with the Judicial Member, leading to the CESTAT's majority decision in favor of the respondent.
The Court's Reasoning
The Supreme Court examined the core issue of whether labelling amounted to manufacture. The Court noted that the definition of 'manufacture' under Section 2(f) of the Central Excise Act includes processes that are incidental or ancillary to the completion of a manufactured product. The Court emphasized that Note 3 to Chapter 18, post-amendment, clearly delineates labelling as an independent process that can constitute manufacture.
The Court highlighted the legislative intent behind the amendment, which replaced 'and' with 'or' in Note 3, thereby allowing for the interpretation that any one of the activities—labelling, repacking, or other treatments—could independently qualify as manufacture. This interpretation aligns with the broader understanding of manufacturing processes under the Central Excise Act.
Statutory Interpretation
The Supreme Court's interpretation of Note 3 to Chapter 18 of the Central Excise Tariff Act was pivotal in its ruling. The amendment to Note 3, which changed the conjunction from 'and' to 'or', was significant in expanding the scope of what constitutes manufacture. The Court concluded that labelling or re-labelling of containers is a distinct process that can stand alone as a manufacturing activity, independent of any repacking activities.
Constitutional or Policy Context
While the judgment primarily focused on statutory interpretation, it also touched upon the broader implications for businesses engaged in manufacturing and exporting goods. The ruling underscores the importance of clarity in legislative language and its impact on compliance and operational practices within the excise framework.
Why This Judgment Matters
This ruling is crucial for businesses involved in manufacturing and exporting goods, particularly in understanding the scope of activities that can be classified as manufacturing under the Central Excise Act. The clarification regarding labelling as a manufacturing process allows companies to avail themselves of cenvat credit and rebates more confidently, reducing the risk of disputes with tax authorities.
Final Outcome
The Supreme Court dismissed the appeal by the revenue, affirming the CESTAT's order that allowed Jindal Drugs Ltd. to claim cenvat credit and rebates based on its labelling activities. The Court's decision reinforces the interpretation of manufacturing processes under the Central Excise Act, particularly in light of the amendments to the relevant provisions.
Case Details
- Case Title: Commissioner of Central Excise Belapur vs Jindal Drugs Ltd.
- Citation: 2024 INSC 354
- Court: IN THE SUPREME COURT OF INDIA
- Bench: ABHAY S. OKA, J & UJJAL BHUYAN, J.
- Date of Judgment: 2024-04-30
